HSD17B13 variants and uses thereof

US11485958B2 · kind B2 · utility

Assignee

• REGENERON PHARMACEUTICALS, INC. · US

Inventors

• Noura S. Abul-Husn · New York, US
• Omri GOTTESMAN · Sierra Sky Park, US
• Alexander Li · White Plains, US
• Xiping Cheng · Millwood, US
• Yurong Xin · Tarrytown, US
• Evangelos Pefanis · Somers, US
• Suzanne Hartford · Putnam Valley, US
• Jesper Gromada · Scarsdale, US
• Frederick Dewey · Winchester, US
• Aris Baras · Tarrytown, US
• Alan Shuldiner · Columbia, US

Key dates

• Filing date: Jul 29, 2020
• Grant date: Nov 1, 2022
• Expiry date: Jul 29, 2040

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/085
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided are compositions related to HSD17B13 variants, including isolated nucleic acids and proteins related to variants of HSD17B13, and cells comprising those nucleic acids and proteins. Also provided are methods related to HSD17B13 variants. Such methods include methods for modifying a cell through use of any combination of nuclease agents, exogenous donor sequences, transcriptional activators, transcriptional repressors, and expression vectors for expressing a recombinant HSD17B13 gene or a nucleic acid encoding an HSD17B13 protein. Also provided are therapeutic and prophylactic methods for treating a subject having or at risk of developing chronic liver disease.